Table 1.
Patient and SCLC treatment characteristics
| Patients with MSM (n=15) |
Patients without MSM or Recurrence (n=180) |
P Value | |
|---|---|---|---|
| Patient Characteristics | |||
| Sex | 0.191 | ||
| Male | 5 | 93 | |
| Female | 10 | 87 | |
| Age at diagnosis, years | 0.918 | ||
| Median (range) | 63.0 (43–78) | 62.0 (34–90) | |
| Year of diagnosis | 1.000 | ||
| <2000 | 5 | 65 | |
| ≥2000 | 10 | 115 | |
| Race | 0.158 | ||
| White | 13 | 141 | |
| Black | 1 | 25 | |
| Hispanic | 0 | 10 | |
| Asian | 0 | 4 | |
| Other | 1 | 0 | |
| Smoking pack-years | 0.21 | ||
| Median (range) | 56.0 (20–160) | 50.0 (0–168) | |
| Smoking status | 1.000 | ||
| Never-smoker | 0 | 4 | |
| Former smoker | 9 | 102 | |
| Current smoker | 6 | 72 | |
| Unknown | 0 | 2 | |
| Treatment Characteristics | |||
| Chemotherapy | 0.843 | ||
| Concurrent chemo-RT | 11 | 122 | |
| Induction chemo followed by concurrent chemo-RT | 2 | 36 | |
| Induction chemo followed by sequential RT | 2 | 22 | |
| Radiation dose, Gy | |||
| Median (range) | 45 (45–70) | 45 (45–70) | 0.532 |
| Mean | 52.4 | 49.6 | 0.1619 |
| Radiation dose, Gy, for pts treated <2000* | 0.757 | ||
| Median (range) | 45 (45–56) | 45 (45–66) | |
| Mean | 49.2 | 47.2 | |
| No. of cases | 5 | 65 | |
| Radiation dose, Gy, for pts treated ≥2000** | 0.811 | ||
| Median (range) | 53.1 (45–70) | 45 (45–70) | |
| Mean | 54.0 | 51.0 | |
| No. of cases | 10 | 115 | |
| PCI | |||
| Yes | 9 | 101 | 1.000 |
| No | 6 | 79 |
Abbreviations: MSM, metachronous second malignancy; pts, patients; chemo, chemotherapy; RT, radiation therapy; PCI, prophylactic cranial irradiation
*
delivered as either 2-dimensional anteroposterior/posteroanterior fields followed by oblique fields or non-conformal 3-dimensional radiation therapy
**
delivered as 3-dimensional conformal or intensity-modulated radiation therapy